These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11701896)

  • 21. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levodopa delivery systems for the treatment of Parkinson's disease: an overview.
    Goole J; Amighi K
    Int J Pharm; 2009 Oct; 380(1-2):1-15. PubMed ID: 19651197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Parkinson's disease and neurotransmitters].
    Narabayashi H
    Nihon Rinsho; 1984 Apr; 42(4):869-74. PubMed ID: 6481982
    [No Abstract]   [Full Text] [Related]  

  • 24. The dopamine transporter: importance in Parkinson's disease.
    Nutt JG; Carter JH; Sexton GJ
    Ann Neurol; 2004 Jun; 55(6):766-73. PubMed ID: 15174010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews.
    Schlossmacher MG; Cullen V; Müthing J
    N Engl J Med; 2005 Feb; 352(7):728-31; author reply 728-31. PubMed ID: 15719451
    [No Abstract]   [Full Text] [Related]  

  • 26. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study.
    Sossi V; de la Fuente-Fernández R; Schulzer M; Troiano AR; Ruth TJ; Stoessl AJ
    Ann Neurol; 2007 Nov; 62(5):468-74. PubMed ID: 17886297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurobiology. Chaperones take flight.
    Helfand SL
    Science; 2002 Feb; 295(5556):809-10. PubMed ID: 11823628
    [No Abstract]   [Full Text] [Related]  

  • 28. Synaptic plasticity, dopamine and Parkinson's disease: one step ahead.
    Calabresi P; Mercuri NB; Di Filippo M
    Brain; 2009 Feb; 132(Pt 2):285-7. PubMed ID: 19168452
    [No Abstract]   [Full Text] [Related]  

  • 29. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Influencing of Parkinson's syndrome via intervention in the dopamine metabolism].
    Korten JJ; van Rossum JM
    Ned Tijdschr Geneeskd; 1973 Feb; 117(8):296-305. PubMed ID: 4350090
    [No Abstract]   [Full Text] [Related]  

  • 31. Rational management of the 'on-off' syndrome in Parkinson's disease.
    Coleman RJ
    Q J Med; 1990 Feb; 74(274):121-31. PubMed ID: 2189148
    [No Abstract]   [Full Text] [Related]  

  • 32. [Etiology and physiopathology of patients with parkinson's disease].
    Ogawa N
    Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1394-9. PubMed ID: 13677885
    [No Abstract]   [Full Text] [Related]  

  • 33. Glial cells and abnormal protein handling in the pathogenesis of Parkinson's disease.
    McNaught KS; Lee M; Hyun DH; Jenner P
    Adv Neurol; 2001; 86():73-82. PubMed ID: 11554011
    [No Abstract]   [Full Text] [Related]  

  • 34. [Extrapyramidal and presenile dementia. Relation between symptoms of dementia and cerebral transmitters, particularly dopamine].
    Kristensen V
    Ugeskr Laeger; 1976 Aug; 138(34):2047-50. PubMed ID: 184570
    [No Abstract]   [Full Text] [Related]  

  • 35. [Pathogenesis of Parkinson's disease: a possibility of oxidation].
    Jiménez-Jiménez FJ; Molina JA; Fernández-Calle P; Cabrera-Valdivia F
    Neurologia; 1993 Apr; 8(4):138-46. PubMed ID: 8517962
    [No Abstract]   [Full Text] [Related]  

  • 36. Gene discovery offers tentative clues to Parkinson's.
    Vogel G
    Science; 1997 Jun; 276(5321):1973. PubMed ID: 9221499
    [No Abstract]   [Full Text] [Related]  

  • 37. Amide-type adduct of dopamine - plausible cause of Parkinson diseases.
    Liu X; Yamada N; Osawa T
    Subcell Biochem; 2014; 77():49-60. PubMed ID: 24374917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of phenothiazines on dopamine metabolism and biochemistry of Parkinson's disease.
    Barbeau A
    Agressologie; 1968; 9(2):195-200. PubMed ID: 5675486
    [No Abstract]   [Full Text] [Related]  

  • 39. Problems in the contemporary treatment of parkinsonism.
    Eadie MJ
    Med J Aust; 1985 Jan; 142(2):113-7. PubMed ID: 2981393
    [No Abstract]   [Full Text] [Related]  

  • 40. L-dopa in Parkinson's disease.
    Horstink MW; van de Vlasakker CJ
    Neurology; 1991 Oct; 41(10):1709. PubMed ID: 1922837
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.